CEO Board Update Seth Berkley, MD 29 November 2017, Vientiane, Lao PDR www.gavi.org
Key developments Previous Board decisions Strategic questions for discussion Alliance update Board agenda Remembering Olga Popova Valued friend to Gavi 2009-2014 as a PPC Member, alternate Board Member & Governance Committee Member Board meeting 29-30 November 2017
Key developments Previous Board decisions Strategic questions for discussion Alliance update Board agenda Lao PDR’s road to transition 87 88 89 82% 79 78 74 Coverage with DTP 67 2017: First year of containing vaccines % 61 accelerated transition 57 52% 53 50 Measles & Rubella 49 49 Inactivated polio 45 Second dose of Pneumococcal Support for immunisation Encephalitis Pentavalent Hepatitis B HPV demo and health systems Japanese strengthening since 2001 Board meeting 29-30 November 2017
1 KEY DEVELOPMENTS IN OUR GLOBAL LANDSCAPE Board meeting 29-30 November 2017
Key developments Key developments Previous Board decisions Strategic questions for discussion Alliance update Board agenda New WHO leadership team New Gavi Board representation Dr Tedros, Director General Dr Soumya Swaminathan Deputy Director-General for Programmes Dr Princess Nothemba (Nono) Simelela Assistant Director-General for Family, Women, Children and Adolescents Bold work plan for 2019-2023; new ways of working, more accountability, outcomes focus & partnership with two important areas for Gavi: • the role immunisation plays in Universal Health Care • the importance of immunisation and how measured in the Sustainable Development Goal indicators Board meeting 29-30 November 2017
Key developments Key developments Previous Board decisions Strategic questions for discussion Alliance update Board agenda The wider benefit of immunisation TERTIARY Towards universal health SECONDARY coverage PRIMARY HEALTH CARE Build out system ROUTINE IMMUNISATION to reach the remainder 86% 14% Children reached through routine immunisation worldwide Board meeting 29-30 November 2017
Key developments Key developments Previous Board decisions Strategic questions for discussion Alliance update Board agenda Leadership changes for partners Tony Lake Peter Sands Search process begun New Global Fund Executive Director for UNICEF leadership Board meeting 29-30 November 2017
Key developments Key developments Previous Board decisions Strategic questions for discussion Alliance update Board agenda Gavi’s work has a direct relationship with 14 of the 17 Sustainable Development Goals Goal 17: Partnership for the Goals Goal 1: No poverty Immunisation progress over Health is Wealth: For every US$ 1 the last few decades was invested in immunisation in low- transformed by a public-private and middle-income countries, approach that combined the there is an estimated US$ 48 net best of both sectors to develop, benefit of longer, healthier lives test, finance and deliver affordable vaccines to more children in need Goal 5: Gender equality Goal 8: Decent work and economic growth In most countries and at the global aggregate level, Parents of immunised and immunisation reaches girls healthy children are able to work and boys equally and engage in economic activity. Healthy children grow into a productive future workforce that builds household incomes and stronger economies Board meeting, 29-30 November 2017
Key developments Key developments Previous Board decisions Strategic questions for discussion Alliance update Board agenda Non-health SDGs setting bold aspirations Board meeting 29-30 November 2017
Key developments Key developments Previous Board decisions Strategic questions for discussion Alliance update Board agenda Immunisation indicator for Sustainable Development Goals PCV last How to measure? MCV2 Likely indicator: • DTP3 DTP3 • PCV last dose • MCV2 • HPV last dose HPV last Long-term goal: • Child-centric view: full immunisation with all 12 vaccines universally recommended by WHO for children & adolescents Board meeting 29-30 November 2017
Key developments Key developments Previous Board decisions Strategic questions for discussion Alliance update Board agenda Vaccine hesitancy, impact in Gavi countries Board meeting 29-30 November 2017
Key developments Key developments Previous Board decisions Strategic questions for discussion Alliance update Board agenda Increasing use of digital platforms to support the alliance’s work Through Social Media watching, we see hesitancy hotspots positive neutral negative Outbreak map, managed by Gavi, housed on Vaccines Work Board meeting 29-30 November 2017
Key developments Key developments Previous Board decisions Strategic questions for discussion Alliance update Board agenda Changes to our donor landscape Donor Country Governments Norway Sweden Netherlands Denmark Germany Republic Japan of Korea United Arab Emirates India Elections New contributions Board meeting 29-30 November 2017
Key developments Key developments Previous Board decisions Strategic questions for discussion Alliance update Board agenda Manufacturer landscape • Leadership changes since last replenishment Vaccine • manufacturers Increasingly diverse & complex supplier landscape 17 vaccines 10 vaccines 18 vaccines (if 567,062,000 doses Number of Gavi Board approves 6 vaccines funded doses typhoid) 6 vaccines 155,690,500 97,913,000 doses 49,901,000 doses doses 2001 2005 2010 2015 2017 Board meeting 29-30 November 2017
Key developments Key developments Previous Board decisions Strategic questions for discussion Alliance update Board agenda Evolution of the penta market how Gavi has been a catalyst for market shaping through growing demand Increasing volumes, changing number of suppliers, reducing price 193.7 m US$ 3.49 doses shipped in 2016 2.8 m 159 m doses requested average of number of doses US$ 1.55 in 2001 shipped across 2017-2019 Predicted to move towards US$ ~0.80 Source: Gavi Base Demand Forecast, based on UNICEF per dose by 2019 Shipment Data Scope: Gavi countries procuring through UNICEF (excluding Indonesia) All data points for Number of Gavi/UNICEF suppliers Number of shipped doses 2017-2019 are estimates Board meeting 29-30 November 2017
Key developments Key developments Previous Board decisions Strategic questions for discussion Alliance update Board agenda New groups to accelerate vaccine R&D 3 targets • Middle East Respiratory Syndrome • Lassa fever • Nipah Based on the potential to become global public health emergencies and have a feasible development approach for a vaccine Next – call for proposals for platform technologies Board meeting 29-30 November 2017
2 REPORTING BACK ON PREVIOUS BOARD DECISIONS Board meeting 29-30 November 2017
Key developments Previous Board decisions Previous Board decisions Strategic questions for discussion Alliance update Board agenda Nigeria in transition case study ‘Nigeria illustrates that focusing on economic indicators alone to determine access to donor financing is a high-risk strategy’ Results UK ‘The impact of UK aid’ November 2017 Board meeting 29-30 November 2017
Key developments Previous Board decisions Previous Board decisions Strategic questions for discussion Alliance update Board agenda Pneumonia & diarrhoea remain leading killers of children Save The Children, October 2017 Johns Hopkins IVAC, November 2017 Board meeting 29-30 November 2017
Key developments Previous Board decisions Previous Board decisions Strategic questions for discussion Alliance update Board agenda Scale-up of immunisation ahead of other pneumonia and diarrhoea interventions • Vaccine coverage performance outweighs non vaccine performance • Of the 15 countries in this report, none met the non-vaccine intervention targets for Pneumonia or Diarrhoea Vaccine Interventions Non-vaccine Interventions Board meeting Source: Johns Hopkins IVAC, November 2017 29-30 November 2017
Key developments Previous Board decisions Previous Board decisions Strategic questions for discussion Alliance update Board agenda LICs Rapid scale-up in pneumococcal conjugate vaccine MICs (Gavi 68) MICs (non-Gavi68) HIC Number of countries Number of countries with PCV introduced PCV3 coverage, % 200 100 170 LIC coverage 155 80 140 150 close to HIC 124 coverage 60 103 100 83 40 57 MICs still 47 50 lagging 30 20 0 0 2008 2009 2010 2011 2012 2013 2014 2015 2016 Board meeting Source: WUENIC data, July 2017 release 29-30 November 2017
Key developments Previous Board decisions Previous Board decisions Strategic questions for discussion Alliance update Board agenda Rotavirus vaccine coverage in low income LICs countries now above high-income MICs (Gavi 68) MICs (non-Gavi68) HIC Number of countries Number of countries with Rota introduced Rota coverage, % LIC coverage 200 50 now above HIC coverage 40 150 30 100 86 82 73 20 53 MICs still 42 50 lagging 30 28 10 23 16 0 0 2008 2009 2010 2011 2012 2013 2014 2015 2016 Board meeting Source: WUENIC data, July 2017 release 29-30 November 2017
Recommend
More recommend
